Kiora Pharmaceuticals, Inc. (KPRX) Stock Price, Financial Report, & Fundamental Analysis

Strength

Analysis	#
Price to Book (PBV) Ratio Undervalued price-to-book. KPRX stock price is under 1x the price-to-book value.
Debt-Equity Ratio (DER) KPRX equity is higher than it's debt.

Weakness

Analysis	#
Market Cap Small market capitalization. Market capitalization is less than 2bn USD
Revenue Growth KPRX has never had growing revenue.
Net Income Growth KPRX has never had growing net income.
Net Income KPRX never has positive net income for 2 years.
Dividend Yield KPRX has low dividend yield (0%).
Return of Assets KPRX has low return of asset (-110.2%).
Return of Equity KPRX has low return of equity (-195.78%).
Revenue KPRX never has positive revenue for 2 years.
Return of Invested Capital KPRX has low ROIC.

Competitors

Financial statements are written records that convey the business activities and the financial performance of a company. Financial statements include the balance sheet, income statement, and statement of cash flow.

Income Statement

Also known as the profit and loss (P&L) statement or the statement of revenue and expense, the income statement primarily focuses on the company’s revenue and expenses during a particular period.

Cashflow Statement

A cash flow statement is a financial statement that provides aggregate data regarding all cash inflows a company receives from its ongoing operations and external investment sources. It also includes all cash outflows that pay for business activities and investments during a given period.

Free Cash Flow

-10,951,537 USD

Dividend

Financial Ratios

CEO

CEO Name

Management

About Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.

Additional Information

Company name

Kiora Pharmaceuticals, Inc.

Symbol

NASDAQ:KPRX

Exchange

NASDAQ Capital Market

Industry

Biotechnology

Sector

Healthcare

Address

1371 East 2100 South
Salt Lake City
UT
US
84105

Website

https://www.kiorapharma.com